Prothena stock plummets following failed Phase 3 trial

Prothena Corporation (PRTA) shares plummeted nearly 25% in after-hours trading after its Phase 3 AFFIRM-AL clinical trial for birtamimab failed to meet its primary endpoint in treating AL amyloidosis, leading to the discontinuation of the drug's development. Consequently, Prothena will significantly reduce its workforce and cut spending to preserve shareholder value, with details to be announced in June. While discontinuing birtamimab, the company remains focused on its pipeline, anticipating data readouts from Alzheimer's and other partnered programs over the next 18 months.

Analysis

Prothena Corporation plc (NASDAQ:PRTA) experienced a significant setback as its shares declined 24.8% in after-hours trading following the announcement that its Phase 3 AFFIRM-AL clinical trial for birtamimab failed to meet its primary endpoint for treating AL amyloidosis. This failure led to the immediate discontinuation of all development for birtamimab, including its open-label extension. The company's leadership, including President and CEO Gene Kinney, expressed surprise and disappointment at the outcome, which also failed to meet secondary endpoints. In response to this development, Prothena plans to implement significant workforce reductions and decrease spending, with specifics to be detailed in June, aiming to preserve shareholder value and align with its revised business strategy. Despite this major trial failure, Prothena is redirecting focus towards its existing pipeline, highlighting upcoming data readouts within the next 18 months, including initial Phase 1 data for PRX012 in Alzheimer’s disease and updates from collaborations with Roche, Novo Nordisk (NYSE:NVO), and Bristol Myers Squibb (NYSE:BMY). The overall sentiment surrounding PRTA is strongly negative, with a market impact score of 0.75, reflecting the gravity of the birtamimab discontinuation.

Key Decisions for Investors

• Investors should recognize the substantial negative impact of the birtamimab trial failure on Prothena's near-term valuation and re-assess their positions given the stock's 24.8% after-hours drop.
• Closely monitor the details of Prothena's planned workforce reduction and spending cuts, to be announced in June, for their potential to stabilize the company's financial position and fund remaining pipeline assets.
• Future investment decisions should heavily weigh the progress and upcoming data from Prothena's remaining pipeline, particularly the Phase 1 ASCENT trials for PRX012 in Alzheimer's and developments from its partnerships, as these now represent key value drivers.
• Consider the increased risk profile of Prothena, as the company now relies more heavily on earlier-stage clinical assets following the discontinuation of a late-stage product candidate.